Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 208-288-1 | CAS number: 520-26-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Effect on fertility: via oral route
- Endpoint conclusion:
- no study available
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
No key-studies regarding fertility of hesperidin are available but in sub-acute and subchronic studies no effects on reproductive organs have been observed, although doses applied in these studies were very high (1% in diet food). Hence, there is currently no suspicion of hesperidin affecting impairment of fertility.
In a supporting study reported, the aim was to investigate the effect of hesperidin on male reproductive system in rats to which methotrexate (MTX) was administered. In the study, 28 male Wistar albino rats at the age of 8 weeks and had 250-300 g of live weight were used. Four experimental groups were formed; Group 1 (n=7): The control group, only feed and water were given. Group 2 (n=7): MTX group, a single dose of 20 mg/kg of i.p. MTX was administered. Group 3 (n=7): Hesperidin group, 200 mg/kg of hesperidin was administered by gavage for 7 days. Group 4: MTX + hesperidin group (n=7): Following administration of a single dose of 20 mg/kg i.p. MTX , 200 mg/kg of Hesperidin was administered by oral gavage for 7 days. At the end of the experiment, rats were decapitated and biochemical, histopathological and spermatological parameters were examined. It was observed that in the MTX group, sperm motility and density, the enzymes CAT, GPx and SOD and GSH level decreased, TNF-alpha and IL-1 Beta, as well as MDA, levels were increased, regular structure of spermatogenic cells was impaired, and seminiferous tubules became necrotic and degenerative. It was determined that spermatological parameters improved and, necrotic and degenerative changes diminished by the administration of MTX+hesperidin. These outcomes indicated that hesperidin had a protective effect on destructive effects of MTX in rat testicles. No negative effects in any of the investigated parameters were seen in the hesperidin dose group.
Effects on developmental toxicity
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 1986
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: fulfill the basical principle, detailed information, performed scientifically
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- not specified
- GLP compliance:
- not specified
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- All the pregnant rats were accommodated one by one in aluminum cages (Made by Natsume Seisakusho Co., Ltd), where solid feed (Oriental Yeast, MF) and tap-water could be freely taken.
Regarding to the animal feeding and breeding room, the temperature was set as 25 ±2 ℃, the relative humidity was set as 55 ±5%, the air exchange rate was set as 15/hr, and the dark-and-light switch rate was set as 12 hours (light period: 6:00-18:00). - Route of administration:
- other: oral administration by stomach tube
- Vehicle:
- water
- Details on exposure:
- Methyl hesperidin was dissolved in distilled water and then given to rats. Since the toxicity of methyl hesperidin is extremely low, by considering its solubility and the dosage of its solution against rats, the dosage was set by 3 stages with the highest level as 8 g/16 ml/kg, following which, divided by common ratio 2, another 2 stages as 4 g/8 ml/kg and 2 g/4 ml/kg were respectively set. During the period from the 7th day to the 17th day of pregnancy including the period of organogenesis of fetuses, oral administration was performed to 19-20 pregnant rats of each group by stomach tube once a day. In addition, 16 ml/kg distilled water was orally given to the rats of the control group as the same.
- Analytical verification of doses or concentrations:
- not specified
- Details on mating procedure:
- In order to get pregnant rats, males were arranged to live together with the nulliparous females all night, the female rats with sperm recognized in vaginal smear next morning were provided for test and this day was taken as the day 0 of pregnancy.
- Duration of treatment / exposure:
- 10 days
- Frequency of treatment:
- once a day
- Duration of test:
- no data
- Dose / conc.:
- 0 mg/kg bw/day
- Remarks:
- control
- Dose / conc.:
- 2 000 mg/kg bw/day
- Dose / conc.:
- 4 000 mg/kg bw/day
- Dose / conc.:
- 8 000 mg/kg bw/day
- No. of animals per sex per dose:
- 19-20 pregnant rats of each group
- Control animals:
- yes, concurrent vehicle
- Maternal examinations:
- The general conditions of the pregnant rats were observed, and the body weight and food consumption were measured on a daily base.
- Ovaries and uterine content:
- On the 20th day of pregnancy, uterus was taken out by cesarean section under ether anesthesia, and corpora lutea count, implantation count and fetal death were checked.
- Fetal examinations:
- Regarding to the living fetuses, the exterior abnormalities were searched by hand-touch and visual contact, and the body weights were measured. Regarding to each matrix, around 1/3 of the living fetuses were fixed for about 2 weeks by Bouin solution, during which, internal organs were checked by Wilson method. After about 2/3 of the rest fetuses were fixed by 90% ethanol, alizarin red stain skeleton specimen were made to check the abnormalities of skeletal system under magnifying glass.
- Statistics:
- The result of test was compared with that of the control group by the levels of P<0.05 and P<0.01 by X2 test (the death rate of maternal rats), t test (body weight, food consumption, corpora lutea count, implantation count, number of fetuses and weight of fetuses) and rank sum test (death rate of fetuses, occurrence rate of morphological abnormality, number of ossification). In addition, as for t test, in case of equal variances, the student’s method was used, in case of unequal variances, the method of Aspin-Welch was used.
- Indices:
- the death rate of maternal rats, death rate of fetuses, occurrence rate of morphological abnormality,
body weight, food consumption, corpora lutea count, implantation count, number of fetuses and weight of fetuses, number of ossification - Historical control data:
- no data
- Details on maternal toxic effects:
- Maternal toxic effects:yes. Remark: One death animal in the mid-dose group, not considered treatment related
Details on maternal toxic effects:
No change in particular was found in food consumption in all the groups with the dose of methyl hesperidin through the entire dosing period, and the body weight gain was also smooth. No abnormality was recognized in general condition either.
As for the maternal rat with all the litter dead, 1 case was recognized in the group of 4 g/kg, however, no significant difference was recognized in occurrence rate. Regarding to the average corpora lutea count, average implantation count and implantation rate, no significant change was recognized in between the control group and the groups with the dose of methyl hesperidin. - Dose descriptor:
- NOAEL
- Effect level:
- 8 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
- Dose descriptor:
- NOAEL
- Effect level:
- 8 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
No significant change was recognized in between the control group and the groups with the dose of methyl hesperidin in average number of fetuses, sex ratio, and average body weight of fetuses.
No abnormal case was observed including the control group in results of visual test.
The cases of dilatation of renal pelvis were observed in each group including the control group by 1.7-4.9%, however, no significant difference was recognized in occurrence rate.
Ossification status was judged by checking the number of metatarsal bones, sacral vertebrae and caudal vertebra, however, no significant difference was recognized from the control group regarding to all of these.
As skeleton deformity, 1 case (0.7%) of the front vertebra of sacral vertebra was observed out of 27 fetuses in the group of 4g/kg, however, no significant difference was recognized in occurrence rate.
Regarding to the fetuses which have skeletal mutation, 113 cases (79.0%) were observed in the control group, 112 cases (76.0%) were observed in the group of 2g/kg, 132 cases (78.8%) were observed in the group of 4g/kg and 139 cases (79.8%) were observed in the group of 8g/kg. Comparing with the control group, no significant difference was recognized in the occurrence rate of each group with the dose of methyl hesperidin. The types of skeletal mutation observed and their occurrence rates were shown as follows. Cervical rib was observed in each group including the control group by 1.7-3.4%.The deformity of cervical lordosis was observed in the group of 8g/kg by 0.6%, the abnormality of thoracic body (deformity, separation) was observed in each group including the control group by 14.2%-18.6%, however, no significant difference was observed in their occurrence rate. In addition, the abnormality of sternebra (deformity, separation and damage) was observed by 43.2%-61.2% in each group including the control group. Lumbar rib (including rudimentary rib) was observed in each group including the control group by 31.0%-42.0%. However, no significant difference was recognized in its occurrence rate. - Dose descriptor:
- NOAEL
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Abnormalities:
- not specified
- Developmental effects observed:
- not specified
- Conclusions:
- There was no evidence of an increase in fetal death or of malformation attributable to the treatment with methyl hesperidin in any of dose levels examined. It is concluded that test substance has no teratogenic effect in rats under the present experimental conditions.
- Executive summary:
The prenatal developmental toxicity test was conducted by orally with Wistar rats. 2, 4 and 8 g/kg of methyl hesperidin were given to the pregnant rats from the 7th day to 17th day of pregnancy including the period of organogenesis of infuses once a day, the effect on the maintenance of pregnancy and the occurrence of fetuses was observed. There was no change recognized in death rate, food consumption and body weight gain for pregnant matrix in all the groups with the dose of test item. Regarding to the fetuses of the 20thday of pregnancy, no significant change was recognized in average number of fetuses, sex ratio and the death rate of fetuses in all the group with the dose of methyl hesperidin. Regarding to the inspection on the outside appearance, skeleton and internal organs, no abnormal case supposed to be derived from the dose of test substance was observed.
Based on the description above, it is concluded that methyl hesperidin is not a teratogen. According to CLP (Regulation EC No.1272/2008), test substance shall not be classified.
Reference
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 8 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
A prenatal developmental toxicity of methyl hesperidin was conducted by oral application with Wistar rats 2, 4 and 8 g/kg bw. the test substance was given to the pregnant rats from the 7th day to 17th day of pregnancy including the period of organogenesis of infuses once a day and the effect on the maintenance of pregnancy and the occurrence of fetuses was observed. There was no change recognized in death rate, food consumption and body weight gain for pregnant matrix in all the groups with the dose of test item. Regarding to the fetuses of the 20thday of pregnancy, no significant change was recognized in average number of fetuses, sex ratio and the death rate of fetuses in all the group with the dose of methyl hesperidin. Regarding to the inspection on the outside appearance, skeleton and internal organs, no abnormal case supposed to be derived from the dose of test substance was observed. In another study (D.H. Waalkens-Berendsen, 2004), the test article at a dietary level of up to 5% (corresponding to an intake of about 3.3 g/kg bw/day) did not exhibit any maternal toxicity, fetotoxicity, embryotoxicity, or teratogenicity in Crl:(WI)WU BR.
Both substances, methyl hesperidin and neohesperidin dihydrochalcone, are structurally very similar to hesperidin. Whereas methyl hesperidin shares the common metabolite hesperetin with the metabolism of hesperidin and thus can be considered as appropriate surrogate for hesperidin, also neohesperidin dihydrochalcone, sharing the next metabolite with hesperidin, resulting from ring cleavage of the central ring in hesperitin is an appropriate surrogate. Methyl hesperidin as structurally more similar to hesperidin than neohesperidin dihydrochalcone has been selected as closest surrogate.
In another supportive study (Gustavo Tadeu Volpato, et al., 2006), a mixture of vitamin C, hesperidin and piperidol was applied to Wistar pregnant rats by oral gavage with 166.5 mg/kg/day to evaluate the reproductive performance and the development of their offspring during the organogenic period (from day 5 to 14 of pregnancy; positive vaginal smear = day 0). There was no alteration in maternal reproductive performance observed, but an increase of the number of fetuses presenting dilated urether, hydronephrosis, and reduced ossification of skull due to the treatment of female rats with the mixture was noted. These abnormalities were considered transitory and may not interfere on offspring development.
No other types of major malformation were observed, neither the appearance of fetuses presenting atrophy of upper limbs that it could be associated to use of this mixture containing piperidol.Justification for selection of Effect on developmental toxicity: via oral route:
The study on hethylhesperidin has been selected as key study, as this substance is structurally extremely similar to hesperidin. It shares the common metabolite hesperetin with the metabolism of hesperidin and thus can be considered as appropriate surrogate for hesperidin. This study is supported by an equivalent study on neohesperidin dihydrochalcone, sharing the next metabolite with hesperidin, resulting from ring cleavage of the central ring in hesperetin.
Toxicity to reproduction: other studies
Additional information
In the absence of any findings regards fertility in sub-acute and sub-chronic studies and given that strucutral analogues such as methyl hesperidin and neohesperidin dihydrochalcone, both sharing similar metabolic pathways with hesperidin (see read across justification in section 13), did not show teratogenic effects, further studies on reproductive toxicity are not required.
Justification for classification or non-classification
Based on the description above, it is concluded that methyl hesperidin is not a teratogen. According to CLP (Regulation EC No.1272/2008) as well as DSD (Directive 67/548/EEC), test substance shall not be classified.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.